Sigyn Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -1,270.0% | -1,270.0% | -181.5% |
| FY2021 | 1,135.6% | 1,135.6% | -423.0% |
| FY2022 | 153.9% | -779.0% | -880.1% |
| FY2023 | 121.5% | 458.2% | -1,288.3% |
| FY2024 | 74.9% | 137.1% | -1,562.9% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -1,270.0% | -1,270.0% | -181.5% |
| FY2021 | 1,135.6% | 1,135.6% | -423.0% |
| FY2022 | 153.9% | -779.0% | -880.1% |
| FY2023 | 121.5% | 458.2% | -1,288.3% |
| FY2024 | 74.9% | 137.1% | -1,562.9% |